Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects
- PMID: 1485372
- DOI: 10.1097/00007691-199212000-00010
Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects
Abstract
The pharmacokinetics of fluvoxamine maleate was studied in two separate studies in healthy young and elderly subjects. In a single and multiple oral dose administration study, six healthy young subjects received an initial 50 mg oral dose followed by 50 mg tablets every 12 h for 28 days. In a second study, 13 elderly subjects received 50 mg tablets every 12 h for 28 days. Fluvoxamine peak plasma concentrations were reached in approximately 5-6 h following oral administration of single and multiple 50 mg doses to healthy young and elderly volunteers. The area under the curve (AUC) of fluvoxamine tended to be larger following multiple (873 ng.h/ml) as compared to single-dose administration (652 ng.h/ml). Also the terminal half-life after chronic dosing (22 +/- 6 h) tended to be longer than after single dosing. Steady-state plasma levels were obtained within 10 days' administration. The pharmacokinetics of fluvoxamine in elderly healthy subjects were no different from those recorded in young subjects. These results suggest that it is not necessary to adjust the dosage of fluvoxamine in elderly depressed patients, on the basis of pharmacokinetic arguments. Independent of the age group, approximately 3% of a dose was recovered as unchanged drug in the urine.
Similar articles
-
Fluvoxamine pharmacokinetics in healthy elderly subjects and elderly patients with chronic heart failure.Br J Clin Pharmacol. 2010 Mar;69(3):279-86. doi: 10.1111/j.1365-2125.2009.03587.x. Br J Clin Pharmacol. 2010. PMID: 20233199 Free PMC article. Clinical Trial.
-
Pharmacokinetics of fluvoxamine maleate in patients with liver cirrhosis after single-dose oral administration.Clin Pharmacokinet. 1993 Feb;24(2):177-82. doi: 10.2165/00003088-199324020-00006. Clin Pharmacokinet. 1993. PMID: 8453824
-
Pharmacokinetics of fluvoxamine maleate after increasing single oral doses in healthy subjects.Biopharm Drug Dispos. 1993 May;14(4):291-6. doi: 10.1002/bdd.2510140403. Biopharm Drug Dispos. 1993. PMID: 8499580 Clinical Trial.
-
Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design.J Clin Psychiatry. 1997;58 Suppl 5:7-14. J Clin Psychiatry. 1997. PMID: 9184622 Review.
-
Clinical pharmacokinetics of fluvoxamine.Clin Pharmacokinet. 1994 Sep;27(3):175-90. doi: 10.2165/00003088-199427030-00002. Clin Pharmacokinet. 1994. PMID: 7988100 Review.
Cited by
-
Pharmacologic treatment of depression in late life.CMAJ. 1997 Oct 15;157(8):1061-7. CMAJ. 1997. PMID: 9347777 Free PMC article. Review.
-
Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.Clin Pharmacokinet. 1997;32 Suppl 1:1-21. doi: 10.2165/00003088-199700321-00003. Clin Pharmacokinet. 1997. PMID: 9068931 Review.
-
Eleven new metabolites of fluvoxamine detected in the solid tissues and body fluids obtained from a deceased overdosed with fluvoxamine in vivo, and the metabolites in the human liver microsomes in vitro using LC-HR-MS/MS.Forensic Toxicol. 2025 Jul;43(2):235-246. doi: 10.1007/s11419-025-00714-7. Epub 2025 Mar 1. Forensic Toxicol. 2025. PMID: 40024989
-
Fluvoxamine as an adjunctive agent in schizophrenia.CNS Drug Rev. 2001 Fall;7(3):283-304. doi: 10.1111/j.1527-3458.2001.tb00200.x. CNS Drug Rev. 2001. PMID: 11607044 Free PMC article. Review.
-
Non-linear fluvoxamine disposition.Br J Clin Pharmacol. 1998 Mar;45(3):257-63. doi: 10.1046/j.1365-2125.1998.00670.x. Br J Clin Pharmacol. 1998. PMID: 9517369 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical